The first data with the RNAi project VIR-2218 mark Vir’s attempt to join a race that Arbutus appeared to crash out of last month.
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Solena is poised to show whether it can sate genetically driven hunger, while the hepatitis B wannabe Arbutus needs to put previous clinical failures behind it.
Arbutus Biopharma already looked second best to Arrowhead Pharmaceuticals in the race to develop a functional cure for hepatitis B. New data have made the former’s task…
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.